Monte Rosa Therapeutics (GLUE) EBIAT (2023 - 2025)
Historic EBIAT for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to -$27.1 million.
- Monte Rosa Therapeutics' EBIAT fell 1350.43% to -$27.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.9 million, marking a year-over-year increase of 11753.73%. This contributed to the annual value of -$72.7 million for FY2024, which is 4630.72% up from last year.
- Latest data reveals that Monte Rosa Therapeutics reported EBIAT of -$27.1 million as of Q3 2025, which was down 1350.43% from -$12.3 million recorded in Q2 2025.
- Over the past 5 years, Monte Rosa Therapeutics' EBIAT peaked at $46.9 million during Q1 2025, and registered a low of -$35.2 million during Q2 2023.
- For the 3-year period, Monte Rosa Therapeutics' EBIAT averaged around -$18.2 million, with its median value being -$30.3 million (2024).
- Examining YoY changes over the last 5 years, Monte Rosa Therapeutics' EBIAT showed a top increase of 24666.23% in 2025 and a maximum decrease of 1350.43% in 2025.
- Monte Rosa Therapeutics' EBIAT (Quarter) stood at -$33.3 million in 2023, then soared by 140.35% to $13.4 million in 2024, then crashed by 301.54% to -$27.1 million in 2025.
- Its EBIAT stands at -$27.1 million for Q3 2025, versus -$12.3 million for Q2 2025 and $46.9 million for Q1 2025.